These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10472432

  • 1. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N, Rambaldi PF, Battista C, Ambrosio G, Cascini GL, Schillirò F, Mansi L.
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [Abstract] [Full Text] [Related]

  • 2. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 3. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 5. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 6. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [Abstract] [Full Text] [Related]

  • 7. Prediction of efficacy of octreotide therapy in patients with acromegaly.
    Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
    [Abstract] [Full Text] [Related]

  • 8. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 9. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D'Angelo V, Scarabino T, Liuzzi A.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 12. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW.
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [Abstract] [Full Text] [Related]

  • 13. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 14. [Hyperthyroidism caused by a TSH producing pituitary adenoma].
    Prasch F, Knosp SE, Steinbach R, Wogritsch S, Hurtl I, Greifeneder M, Holm C, Najemnik C, Dudczak R.
    Acta Med Austriaca; 1999 Dec; 26(1):32-6. PubMed ID: 10230475
    [Abstract] [Full Text] [Related]

  • 15. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.
    Lamberts SW, de Quijada M, Klijn JG.
    J Endocrinol Invest; 1980 Dec; 3(4):343-7. PubMed ID: 7204884
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 17. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M, Yamaji T.
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [Abstract] [Full Text] [Related]

  • 18. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
    Garcia MB, Koppeschaar HP, Lips CJ, Thijssen JH, Krenning EP.
    J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
    [Abstract] [Full Text] [Related]

  • 19. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F, Cesselin F, Bression D, Zygelman N, Brandi AM, Nousbaum A, Mauborgne A.
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [Abstract] [Full Text] [Related]

  • 20. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.